Preclinical evidence suggests that cancers with the AKT1E17K mutation are more resistant to AKT1 allosteric inhibitors.[28] To detect whether SVIL‐AS1 affected the response to AKT1 allosteric inhibitor, we performed MTS assays and found that SVIL‐AS1 knockdown sensitized both MCF‐10A and AKT1E17K cells to AKT1 allosteric inhibitor MK2206, and the effect was more dramatic in AKT1E17K cells (Figure5A). Here, SVIL-AS1 is linked to cancer.